Regarded Solutions
Portfolio strategy

Achillion: Is This Stock For Traders Or For Long Term Investors?

I have been following Achillion Pharmaceuticals (NASDAQ:ACHN) since October, 2012. My first article (click here) was an in-depth look at the company and the exciting developments of their drug pipeline, to treat, and potentially cure, Hepatitis C.

The stock has bounced around since that first article, and the movement has been rather interesting, but certainly not unusual in the small cap bio-tech world.

The stock was highest when I first wrote about it, and with subsequent follow up articles as well. As you can see from this chart, the most recent upward move has coincided with the recent presentations that the company has made during the month of May.

I outlined these presentation dates in this...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details